{"_links":{"self":[{"href":"/project/GID-TA10730"}]},"_embedded":{"nice.indev:timeline-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:timeline":[{"_links":{"self":[{}]},"ETag":null,"Column1":"21 February 2023 - 14 March 2023","Column2":"Draft guidance: 2","AdditionalInfoLabel":null,"AdditionalInfo":"2","Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"12 January 2023","Column2":"Committee meeting: 2","AdditionalInfoLabel":"Meeting number","AdditionalInfo":"2","Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"12 October 2022 - 02 November 2022","Column2":"Draft guidance","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"04 February 2022","Column2":"The timelines for this appraisal have been amended. The appraisal committee meeting is now scheduled to take place on Thursday 15 September 2022.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"03 November 2021","Column2":"Invitation to participate","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"16 July 2021","Column2":"Please note that following on from advice received from the company the timelines for this appraisal have been revised.\r\nFor information, we anticipate that the appraisal will now begin during early November 2021.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"08 June 2021 - 06 July 2021","Column2":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"01 September 2020","Column2":"In progress. DHSC referral received","AdditionalInfoLabel":"Link text","AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:process-homepage":{"_links":{"self":[{"href":"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation"},{}]},"ETag":null,"Description":"For further information on our processes and methods, please see our","LinkText":"CHTE processes and methods manual"},"nice.indev:project-team-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:project-team":{"_links":{"self":[{}]},"ETag":null,"Column1":"Project lead","Column2":"Thomas Feist"}},"ETag":null},"nice.indev:email-enquiry-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:email-enquiry":{"_links":{"self":[{}]},"ETag":null,"Item":"TAteam1@nice.org.uk"}},"ETag":null},"nice.indev:consultee-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultee":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Companies sponsors","Column2":"Novartis Pharmaceuticals"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Department of Health and Social Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"NHS England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"Welsh Govenment"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Prostate Cancer UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"Tackle prostate cancer"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Association of Cancer Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"British Nuclear Medicine Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Cancer Research UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"Royal College of Radiologists"}]},"ETag":null},"nice.indev:commentator-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:commentator":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"Bayer"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"All Wales Therapeutics and Toxicology Centre"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"British National Formulary"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Department of Health, Social Services and Public Safety - Northern Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Healthcare Improvement Scotland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Medicines and Healthcare Products Regulatory Agency"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Scottish Medicines Consortium"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"Welsh Health Specialised Services Committee"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"Institute of Cancer Research"}]},"ETag":null},"nice.indev:panel-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:panel":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/html-content-7"}]},"ETag":null,"Id":"6dacd566-998f-4629-88ba-2f47d8cb4b68","MimeType":"text/html","FileName":"HtmlContent","Length":2361,"Hash":"DBE1BA32ADBFBDA9C5A6905D2CCF22B8BE6B4536","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"html-content-7","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft guidance: 2","Level":1,"PublishedDate":"2023-02-21T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2099,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/129-2"}]},"ETag":null,"Id":"d4710287-01f7-4788-86ac-a35463bdd5c4","MimeType":"application/pdf","FileName":"1. ID3840 177lu vipivotide tetraxetan for mCRPC ACM2 to PM for consultation [NoACIC].pdf","Length":386963,"Hash":"01FBF044F41231B8BA1EB1A8FEDF70D449B6C74A","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"129-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Appraisal consultation document  (PDF version) 2","Level":1,"PublishedDate":"2023-02-21T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2099,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/committee-papers-2"}]},"ETag":null,"Id":"ff4f3b9e-562f-42ba-9b5f-e3cc6a4072fc","MimeType":"application/pdf","FileName":"2. ID3840 lu vipivotide tetraxetan in mCRPC ACM2 Committee Papers  [redacted].pdf","Length":2466031,"Hash":"BF1FACE7C0136AE3A35126554420DFDBC0DD0E06","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"committee-papers-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers - ACM2","Level":1,"PublishedDate":"2023-02-21T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2099,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/1-2"}]},"ETag":null,"Id":"aeacb8a8-326c-40d6-b543-e84227aba753","MimeType":"application/pdf","FileName":"3. ID3840 lu vipivotide tetraxetan in mCRPC ACM2 post cmt slides for public [redacted].pdf","Length":1300897,"Hash":"F580E4565080ECFBD5DCD6E6292B30C8947AA8AB","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"1-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Public committee slides - ACM2","Level":1,"PublishedDate":"2023-02-21T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2099,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/97-2"}]},"ETag":null,"Id":"891c11d0-7575-42f0-90aa-1a719b299510","MimeType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","FileName":"Appraisal Consultation Document.docx","Length":83877,"Hash":"342AAE503FE4C4CC674475D7786BA44F9711F316","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"97-2","ConsultationDocumentId":3}},"ETag":null,"Title":"Appraisal consultation document (online commenting) 2","Level":1,"PublishedDate":"2023-02-21T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2099,"ConsultationDocumentId":3,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":true,"SupportsComments":true}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance: 2","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/committee-papers-2"}]},"ETag":null,"Id":"ff4f3b9e-562f-42ba-9b5f-e3cc6a4072fc","MimeType":"application/pdf","FileName":"2. ID3840 lu vipivotide tetraxetan in mCRPC ACM2 Committee Papers  [redacted].pdf","Length":2466031,"Hash":"BF1FACE7C0136AE3A35126554420DFDBC0DD0E06","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"committee-papers-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers - ACM2","Level":1,"PublishedDate":"2023-02-21T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":2099,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance: 2","PanelType":"Evidence","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"ETag":null,"HasResources":false}},"ETag":null,"Title":"Committee meetings","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/html-content-2"}]},"ETag":null,"Id":"02368e02-ac9b-44f6-b1bc-72e36a5a5c3e","MimeType":"text/html","FileName":"HtmlContent","Length":2343,"Hash":"6FA340176F625CB8B8C37C24E3709A4D5DA4AE71","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"html-content-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft guidance","Level":1,"PublishedDate":"2022-10-12T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1939,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/97"}]},"ETag":null,"Id":"062e1829-fd4c-455f-beb8-a8de3d0e5b8c","MimeType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","FileName":"1. ID3840 177lu vipivotide tetraxetan for mCRPC ACD to PM for consultation [NoACIC] WEB.docx","Length":76163,"Hash":"20AFE49BCF6E6071010E4CF96629D42719B1BCB6","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"97","ConsultationDocumentId":1}},"ETag":null,"Title":"Appraisal consultation document (online commenting)","Level":1,"PublishedDate":"2022-10-12T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1939,"ConsultationDocumentId":1,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":true,"SupportsComments":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/129"}]},"ETag":null,"Id":"051dcf06-3c9d-475a-aacd-6ba94f3f3006","MimeType":"application/pdf","FileName":"1. ID3840 177lu vipivotide tetraxetan for mCRPC ACD for consultation [NoACIC].pdf","Length":369281,"Hash":"A51203079F8CE9C2616C3FAD8220D8170D307C49","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"129","ConsultationDocumentId":0}},"ETag":null,"Title":"Appraisal consultation document  (PDF version)","Level":1,"PublishedDate":"2022-10-12T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1939,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/committee-papers"}]},"ETag":null,"Id":"8f4f4bfc-7f26-4458-a729-9fd03228511d","MimeType":"application/pdf","FileName":"2. ID3840 lu vipivotide tetraxetan in mCRPC ACD committee papers [redacted].pdf","Length":8358840,"Hash":"D34A980C8E88D342D351E4AECA57DB723A573FC1","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"committee-papers","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers - ACM1","Level":1,"PublishedDate":"2022-10-12T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1939,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/1"}]},"ETag":null,"Id":"cbd33fbe-5ccb-4f86-bf48-40a5783ca381","MimeType":"application/pdf","FileName":"3. ID3840 lu vipivotide tetraxetan in mCRPC slides for public [redacted].pdf","Length":1567306,"Hash":"EFE652C8DAF97EB422898B7AD4957713213BA5DD","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"1","ConsultationDocumentId":0}},"ETag":null,"Title":"Public committee slides - ACM1","Level":1,"PublishedDate":"2022-10-12T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1939,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/committee-papers"}]},"ETag":null,"Id":"8f4f4bfc-7f26-4458-a729-9fd03228511d","MimeType":"application/pdf","FileName":"2. ID3840 lu vipivotide tetraxetan in mCRPC ACD committee papers [redacted].pdf","Length":8358840,"Hash":"D34A980C8E88D342D351E4AECA57DB723A573FC1","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"committee-papers","ConsultationDocumentId":0}},"ETag":null,"Title":"Committee papers - ACM1","Level":1,"PublishedDate":"2022-10-12T00:01:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1939,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Draft guidance","PanelType":"Evidence","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/html-content-5"}]},"ETag":null,"Id":"4ae430d7-fa7c-428c-a7ea-440e1a18a385","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"html-content-5","ConsultationDocumentId":0}},"ETag":null,"Title":"Invitation to participate","Level":1,"PublishedDate":"2023-01-31T12:10:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/final-matrix"}]},"ETag":null,"Id":"6210c0f9-e820-42b7-b842-36049e23ded3","MimeType":"application/pdf","FileName":"ID3840 Prostate cancer - 177Lu-PSMA-617 - stakeholder list v0.3 SW.pdf","Length":168753,"Hash":"DC76257F7492DB2546630ECDBA38B3E8328AF020","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"final-matrix","ConsultationDocumentId":0}},"ETag":null,"Title":"Final stakeholder list","Level":1,"PublishedDate":"2021-11-03T15:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/equality-impact-assessment-scoping"}]},"ETag":null,"Id":"95c12079-5c85-4801-9910-379839738499","MimeType":"application/pdf","FileName":"ID3840 ITP EIA form scoping to PM prostate 177LU-PSMA-617.pdf","Length":126938,"Hash":"6FA518DFC8687B8F6B8661A5A3D20FB64B796A94","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"equality-impact-assessment-scoping","ConsultationDocumentId":0}},"ETag":null,"Title":"Equality impact assessment (Scoping)","Level":1,"PublishedDate":"2021-11-03T15:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/scope-consultation-comments-and-responses"}]},"ETag":null,"Id":"883d82d8-198c-4ddd-861a-187c74023755","MimeType":"application/pdf","FileName":"ID3840 Scoping consultation comments table v0.3 SW [redacted] .pdf","Length":555317,"Hash":"97225E35DE78324A04BC85753FDD4798B2437CD2","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"scope-consultation-comments-and-responses","ConsultationDocumentId":0}},"ETag":null,"Title":"NICE's response to comments on the draft scope and provisional stakeholder list","Level":1,"PublishedDate":"2021-11-03T15:59:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/final-scope-2"}]},"ETag":null,"Id":"eaf80db8-b896-45ae-8051-cf3dbf762317","MimeType":"application/pdf","FileName":"ID3840 prostate cancer 177 LuPSMA-617 updated final scope [re-scope] (noACIC) SM Sep22.pdf","Length":228170,"Hash":"DD09B501E63F2B6C8007D34B5F54A9D3039DCF76","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"final-scope-2","ConsultationDocumentId":0}},"ETag":null,"Title":"Final scope","Level":1,"PublishedDate":"2022-09-22T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Invitation to participate","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/html-content"}]},"ETag":null,"Id":"bc9d1534-c09d-4fb0-b9eb-f4e8ab38a03e","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"html-content","ConsultationDocumentId":0}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","Level":1,"PublishedDate":"2021-06-08T09:14:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1370,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/draft-scope-post-referral"}]},"ETag":null,"Id":"d6f91ab5-ff1e-48e5-8b5c-5df5ed5a5b05","MimeType":"application/pdf","FileName":"Appendix B - Draft scope.pdf","Length":247740,"Hash":"752243DB11ACF9C4AF7F08D4BD6157BD740C6ADB","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"draft-scope-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft scope post referral","Level":1,"PublishedDate":"2021-06-08T09:14:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1370,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-TA10730/documents/draft-matrix-post-referral"}]},"ETag":null,"Id":"b9aabd37-d708-40d9-94f5-f5bd638fa50d","MimeType":"application/pdf","FileName":"Appendix C - stakeholder list.pdf","Length":168520,"Hash":"0E36DD87F0128E66B937423E5446B172C80AB798","Name":"default","Reference":"GID-TA10730","ResourceTitleId":"draft-matrix-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft matrix post referral","Level":1,"PublishedDate":"2021-06-08T09:14:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1370,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true}]},"ETag":null}},"ETag":"01000000-0000-0036-0000-000000000139","Summary":"Suggested remit: To appraise the clinical and cost effectiveness of 177Lu-PSMA-617 within its marketing authorisation for treating prostate-specific membrane antigen (PSMA) positive, hormone-relapsed metastatic prostate cancer previously treated with androgen receptor directed therapy (ARDT) and taxane based chemotherapy. ","Description":null,"ReferralDate":null,"SuspendDiscontinuedReason":null,"SuspendDiscontinuedUrl":null,"SuspendDiscontinuedUrlText":null,"LegacyModel":false,"ProductReference":null,"EvidenceAssessmentGroup":"School of Health and Related Research (ScHARR), University of Sheffield","Reference":"GID-TA10730","ProjectType":"TA","TechnologyType":"Medicine","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2023-02-21T00:01:36.0848451","FirstGoLiveDate":"2020-09-07T13:48:06.5053677","CreatedDate":"2020-09-07T13:46:50.7450324","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3840","AreasOfInterestList":[],"TopicSelectionDecision":"Selected","TopicSelectionReason":null,"TopicSelectionDecisionDate":null,"TopicSelectionFurtherInfo":null,"IndicatorSubTypes":[]}